FYI. You'll have to contact them to see if they are even measuring 100% recovery.
Here is your business101 requirements. Not measuring 100% recovery is the height of incompetence!
“What's measured, improves.” So said management legend and author Peter F. Drucker !
Ask your competent? doctor to explain the
previous FDA hold on this research and notify you of the results when
research is completed. No knowledge of this at all is fucking complete
incompetence! I expect my doctors and therapists to be completely up to
date on all research in the stroke field. You should be getting this
information from your doctor, not me.
DM199
(3 posts to August 2022)
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
Study Overview
Brief Summary
This is a Phase 2/3 study evaluating the safety and efficacy of DM199 (rinvecalinase alfa) in treating participants with moderate stroke severity, who present within 24 hours of Acute Ischemic Stroke (AIS) onset due to small and medium vessel occlusions. This study focuses on participants with limited treatment options. Participants who have or will receive mechanical thrombectomy (MT) are not eligible for participation. Additionally, participants who have received fibrinolytics are excluded unless they experience a persistent neurological deficit of moderate severity six or more hours after fibrinolytic treatment. Participants considered for this trial should not be denied the use of standard of care (SoC) AIS therapies, such as fibrinolytics or MT, when appropriate. The double-blinded study will be randomized and placebo-controlled at up to approximately 100 sites.
To learn more, visitClinicalTrials.gov
